CopyMark Law Group
4.9/5
Drawing for CAPDRIVE

USPTO serial 79370455

CAPDRIVE

Reviewed by CopyMark Law Group

Reg. 7561433Status 700Registered
Filing date
Status date
Registration date
Nov 12, 2024
Examiner
CARROLL, DORITT
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with CAPDRIVE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael T. Smith

Michael T. Smith Birch Stewart Kolasch & Birch LLP8110 Gatehouse Road, Suite 100EBeijing Global Trade Center,Falls Church, VA 22042

Goods and services

ClassDescriptionStatusFirst use
005Stem cells for medical purposes; biochemical medicine for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; biological preparations for medical purposes, namely, for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; biological tissue cultures for medical purposes; chemical preparations for medical purposes, namely, for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; chemical preparations for pharmaceutical purposes, namely, for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; chemico-pharmaceutical preparations for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of ophthalmic, neurological, cardiovascular, and metabolic diseases; cardiovascular pharmaceutical preparations; pharmaceutical preparations for the central nervous system; ophthalmological preparations; pharmaceutical preparations for the treatment of immune system related diseases and disorders; cardiovascular agents for medical purposes; cellular function activating agents for medical purposes; pharmaceutical products for the prevention and treatment of cancerACTIVE—
042Scientific research and development; scientific research; technological research, namely, research on the subject of pharmaceuticals; biological research; scientific research in the nature of conducting clinical trials for others; medical research; pharmaceutical research services; research on the subject of pharmaceuticals; conducting early evaluations in the field of new pharmaceuticals; structural and functional analysis of genomes; biotechnology research; analysis of the mode of action of chemical combinations on animals; research and development services in the field of antibodies; genetic testing for scientific research purposes; biological research and analysis; pharmaceutical drug development services; DNA screening for scientific research purposes; medical research; testing of pharmaceuticals; biomedical research servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 3, 2025FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 11, 2025FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 11, 2025FIMPFINAL DISPOSITION PROCESSED—
Feb 12, 2025FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Nov 12, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Nov 12, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 9, 2024OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Oct 23, 2024OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Oct 23, 2024OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Aug 27, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 27, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 7, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 22, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 19, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 19, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 19, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 14, 2024RFNTREFUSAL PROCESSED BY IB—
Jan 19, 2024RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jan 19, 2024RFRRREFUSAL PROCESSED BY MPU—
Dec 2, 2023RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Dec 1, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 1, 2023DOCKASSIGNED TO EXAMINER—
May 30, 2023MAFRAPPLICATION FILING RECEIPT MAILED—
May 26, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 25, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance